Permanens Capital’s Novavax NVAX Stock Holding History

Permanens Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-105	Closed	-$22K	–	84
2021 Q2	$22K	Hold	105	–	–	﹤0.01%	73
2021 Q1	$19K	Hold	105	–	–	﹤0.01%	91
2020 Q4	$12K	Buy	+105	New	+$11.2K	﹤0.01%	97

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Permanens Capital's NVAX Position: Q3 2021 in Review

Permanens Capital sold out of Novavax (NVAX) in Q3 2021, closing a stake of 105 shares — an estimated $22K sold.

Permanens Capital first reported a position in NVAX in Q4 2020 and held it in 3 quarters. The position peaked at $22K in Q2 2021. 443 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

Permanens Capital reported no remaining Novavax position as of Q3 2021 after selling out during the quarter.
Permanens Capital sold 105 Novavax shares in Q3 2021, an estimated $22K.
Permanens Capital first reported a position in Novavax in Q4 2020 and held it in 3 quarters.
Permanens Capital's Novavax position peaked at $22K in Q2 2021.
443 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on Permanens Capital's 13F filing for Q3 2021, filed 12 Nov 2021.